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Purpose of the study
Mitochondrial toxicity of antiretroviral treatment (ARVT),
especially nucleoside-analogues' capacity to inhibit DNA-
polymerase gamma, has been proposed as the ethio-
pathological mechanism which underlies many of the sec-
ondary effects of HIV therapy. The aim of the present
study was to evaluate whether a prolonged CD4 cell-
guided ARVT interruption could reverse mitochondrial
toxicity.
Methods
We included 38 patients from the TIBET study whose
peripheral blood mononuclear cells (PBMCs) had been
collected at baseline, at 96 and at 144 weeks throughout
the study period; 18 of them discontinued ARVT along
this time and 20 maintained therapy. Mitochondrial DNA
(mtDNA) content was measured by real-time PCR and
mitochondrial function through the spectrophotometric
measurement of cytochrome C oxidase (COX) enzymatic
activity normalised by mitochondrial content using citrate
synthase (CS) activity (COX/CS ratio).
Summary of results
Whereas mtDNA content showed a similar progressive
decrease throughout the study period in both study arms,
only for the control group was this significant either at
week 96 (15% decrease, p = 0.03) or at week 144 (34%
decrease, p = 0.01). The COX/CS ratio significantly
improved in patients who interrupted antiretroviral ther-
apy in comparison with those who did not, especially at
week 96 (130% increase, p = 0.06). The univariate and
multivariate analysis performed showed that only CD4+
T-cell value at the time of ARVT initiation and time with
viral suppression before the study were associated with
changes in the COX/CS ratio.
Conclusion
PBMCs' mitochondrial function improved during a pro-
longed ARVT interruption in spite of mtDNA content
decrease. The absence of correlation between mitochon-
drial parameters suggests the existence of a mitochondrial
transcriptional or translational upregulation mechanism
which could be increasing mitochondrial protein expres-
sion in the absence of mtDNA content improvement, or
also could be the reversion of an ARV-mediated mito-
chondrial toxicity mechanism that was previously disturb-
ing mitochondrial function through a DNA polymerase
gamma-independent way.
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